Eli Lilly And Co (NYSE:LLY) major shareholder Eli & Co Lilly sold 4,500 shares of the firm’s stock in a transaction that occurred on Monday, September 10th. The stock was sold at an average price of $14.44, for a total transaction of $64,980.00. Following the completion of the sale, the insider now directly owns 3,915,654 shares in the company, valued at $56,542,043.76. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Major shareholders that own more than 10% of a company’s stock are required to disclose their sales and purchases with the SEC.
Eli & Co Lilly also recently made the following trade(s):
- On Monday, August 13th, Eli & Co Lilly sold 4,531 shares of Eli Lilly And Co stock. The stock was sold at an average price of $14.33, for a total transaction of $64,929.23.
LLY stock traded up $0.33 during midday trading on Wednesday, reaching $105.97. 3,915,000 shares of the company’s stock traded hands, compared to its average volume of 4,144,857. The stock has a market cap of $114.95 billion, a price-to-earnings ratio of 24.75, a price-to-earnings-growth ratio of 1.78 and a beta of 0.27. The company has a quick ratio of 1.09, a current ratio of 1.40 and a debt-to-equity ratio of 0.79. Eli Lilly And Co has a fifty-two week low of $73.69 and a fifty-two week high of $107.84.
Eli Lilly And Co (NYSE:LLY) last announced its quarterly earnings results on Tuesday, July 24th. The company reported $1.50 earnings per share for the quarter, beating analysts’ consensus estimates of $1.30 by $0.20. The firm had revenue of $6.36 billion for the quarter, compared to analysts’ expectations of $6.05 billion. Eli Lilly And Co had a negative net margin of 0.60% and a positive return on equity of 39.84%. Eli Lilly And Co’s revenue was up 9.1% compared to the same quarter last year. During the same period in the previous year, the company posted $1.11 earnings per share. equities analysts forecast that Eli Lilly And Co will post 5.47 EPS for the current fiscal year.
The firm also recently declared a quarterly dividend, which was paid on Monday, September 10th. Shareholders of record on Wednesday, August 15th were given a dividend of $0.5625 per share. The ex-dividend date was Tuesday, August 14th. This represents a $2.25 dividend on an annualized basis and a yield of 2.12%. Eli Lilly And Co’s dividend payout ratio (DPR) is 52.57%.
A number of hedge funds have recently made changes to their positions in the business. Integrated Wealth Concepts LLC acquired a new position in shares of Eli Lilly And Co during the second quarter worth $103,000. Bay Colony Advisory Group Inc d b a Bay Colony Advisors acquired a new position in shares of Eli Lilly And Co during the second quarter worth $114,000. Legacy Advisors LLC lifted its position in shares of Eli Lilly And Co by 118.0% during the second quarter. Legacy Advisors LLC now owns 1,354 shares of the company’s stock worth $116,000 after purchasing an additional 733 shares in the last quarter. Fort L.P. acquired a new position in shares of Eli Lilly And Co during the second quarter worth $121,000. Finally, Financial Management Professionals Inc. acquired a new position in shares of Eli Lilly And Co during the second quarter worth $128,000. 76.55% of the stock is currently owned by hedge funds and other institutional investors.
Several equities research analysts recently issued reports on the stock. TheStreet raised shares of Eli Lilly And Co from a “c+” rating to a “b” rating in a research report on Friday, June 29th. Zacks Investment Research raised shares of Eli Lilly And Co from a “hold” rating to a “buy” rating and set a $100.00 target price on the stock in a research report on Wednesday, July 18th. Bank of America raised their target price on shares of Eli Lilly And Co from $90.00 to $94.00 and gave the stock a “neutral” rating in a research report on Wednesday, July 25th. Barclays set a $98.00 target price on shares of Eli Lilly And Co and gave the stock a “buy” rating in a research report on Tuesday, May 22nd. Finally, BMO Capital Markets raised their target price on shares of Eli Lilly And Co from $78.00 to $80.00 and gave the stock a “$89.43” rating in a research report on Thursday, July 19th. One research analyst has rated the stock with a sell rating, seven have issued a hold rating and eleven have assigned a buy rating to the company’s stock. Eli Lilly And Co has an average rating of “Buy” and a consensus price target of $100.69.
Eli Lilly And Co Company Profile
Eli Lilly and Company discovers, develops, manufactures, and markets pharmaceutical products worldwide. The company operates through two segments, Human Pharmaceutical Products and Animal Health Products. It offers endocrinology products for the treatment of diabetes; osteoporosis in postmenopausal women and men; and human growth hormone deficiency and pediatric growth conditions.
Featured Article: Risk Tolerance
Receive News & Ratings for Eli Lilly And Co Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly And Co and related companies with MarketBeat.com's FREE daily email newsletter.